𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunosuppression and hepatocellular carcinoma

✍ Scribed by Hans J. Schlitt; Françoise Mornex; Abraham Shaked; James F. Trotter

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
63 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis

Immunosuppressive medications inhibit the tumor surveillance properties of the immune system. Consequently, immunosuppression may increase the likelihood of hepatocellular carcinoma (HCC) recurrence after liver transplantation. However, most data on the effects of immunosuppression on HCC recurrence have been derived from experimental studies (in vitro and animal studies) and from nonrandomized, singlecenter reports. No randomized trials evaluating the effects of immunosuppressive agents on HCC recurrence after liver transplantation have been published. Therefore, the precise effects of immunosuppression on HCC recurrence in liver transplant recipients are difficult to assess.

📜 SIMILAR VOLUMES

Sirolimus-based immunosuppression follow
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
✍ Michael A. Zimmerman; James F. Trotter; Michael Wachs; Tom Bak; Jeffrey Campsen; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

Experience with sirolimus (SRL)-based immunosuppression following orthotopic liver transplantation (OLT) is rapidly accumulating. In combination with calcineurin inhibitors (CNIs), SRL may reduce the incidence of acute rejection and lower overall required drug levels. This study sought to quantify l

Sirolimus-based immunosuppression is ass
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma
✍ Christian Toso; Shaheed Merani; David L. Bigam; A.M. James Shapiro; Norman M. Kn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 1 views

Liver transplantation is an important treatment option for selected patients with nonresectable hepatocellular carcinoma (HCC). Several reports have suggested a lower risk of posttransplant tumor recurrence with the use of sirolimus and a higher one with calcineurin inhibitors, but the selection of

Sirolimus-based immunosuppression for li
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma
✍ Norman M. Kneteman; José Oberholzer; Mohammed Al Saghier; Glenda A. Meeberg; Mau 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

An increasing number of patients with hepatocellular carcinoma (HCC) are undergoing evaluation for listing for liver transplantation. Criteria for selection require ongoing review for suitability. A consecutive series of 40 patients with HCC within the standard Milan criteria (single tumors n = 19 <

Analysis of risk factors for tumor recur
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression
✍ Marco Vivarelli; Alessandro Cucchetti; Fabio Piscaglia; Giuliano La Barba; Luigi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

To confirm recent observations about the relationship between immunosuppression and the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), we retrospectively analyzed 70 consecutive HCC patients who underwent LT and received cyclosporine (CsA) -based immunosuppression. Cs

Hepatocellular carcinoma
Hepatocellular carcinoma
✍ Hiroshi Takagi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views